Treatment with ML385 resulted in a decrease in NRF2 expression, which in turn reduced the expression of the downstream target gene HO1, leading to G1/S phase arrest and a decrease in the survival rate of head and neck cancer cells. This evidence concerns the gene HMOX1 and head and neck cancer.